Insider Transactions in Q4 2022 at Glycomimetics Inc (GLYC)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 30
2022
|
Scott D Sandell > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
121,335
-1.34%
|
$364,005
$3.02 P/Share
|
|
Dec 22
2022
|
Edwin Rock Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
110,000
+26.19%
|
$220,000
$2.25 P/Share
|
|
Nov 17
2022
|
Daniel M Junius |
BUY
Open market or private purchase
|
Direct |
20,000
+24.02%
|
$20,000
$1.87 P/Share
|
|
Nov 15
2022
|
Edwin Rock Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
100,000
+33.33%
|
$100,000
$1.66 P/Share
|
|
Nov 14
2022
|
Edwin Rock Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
100,000
+50.0%
|
$100,000
$1.43 P/Share
|
|
Nov 11
2022
|
Armand Girard SVP, Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
6,500
+18.23%
|
$6,500
$1.05 P/Share
|
|
Nov 11
2022
|
John L. Magnani SVP of Research, CSO |
BUY
Open market or private purchase
|
Direct |
45,045
+10.96%
|
$45,045
$1.17 P/Share
|
|
Nov 11
2022
|
Brian M. Hahn SVP Finance, CFO |
BUY
Open market or private purchase
|
Direct |
20,000
+26.03%
|
$20,000
$1.06 P/Share
|
|
Nov 11
2022
|
Harout Semerjian Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+50.0%
|
$25,000
$1.29 P/Share
|
|
Nov 11
2022
|
Timothy R Pearson |
BUY
Open market or private purchase
|
Direct |
19,400
+44.04%
|
$19,400
$1.29 P/Share
|